Logo

Surrogate Endpoints Show Mixed Value in Breast Cancer Trials

Surrogate Endpoints Show Mixed Value in Breast Cancer Trials

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete response, invasive disease-free survival, and overall survival were analyzed.

👉 Full Story